<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05080283</url>
  </required_header>
  <id_info>
    <org_study_id>CLTD5810</org_study_id>
    <nct_id>NCT05080283</nct_id>
  </id_info>
  <brief_title>Acceptance and Performance of CP1110 Sound Processor With Experienced Adult Cochlear Implant Recipients.</brief_title>
  <acronym>PINNA</acronym>
  <official_title>A Pre-Marketing, Prospective, Single-Site, Open-Label, Within-Subject, Actual-Use, Interventional Study of Acceptance and Performance With Experienced Adult Cochlear Implant Recipients Using the CP1110 Sound Processor Compared With the CP1000 Sound Processor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cochlear</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Avania</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cochlear</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical study aims to investigate acceptance, actual-use usability and speech&#xD;
      performance with a new behind-the-ear sound processor (model number: CP1110) system, compared&#xD;
      with the commercially available Nucleus 7 Sound Processor (model: CP1000) system, with&#xD;
      particular focus on the acceptance of and satisfaction with a noise reduction feature in the&#xD;
      Automatic Scene Classifier 'SCAN'.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical study aims to investigate acceptance, actual-use usability and speech&#xD;
      performance with a new behind-the-ear sound processor (model number: CP1110) system, compared&#xD;
      with the commercially available Nucleus 7 Sound Processor (model: CP1000) system, with&#xD;
      particular focus on the acceptance of and satisfaction with a noise reduction feature in the&#xD;
      Automatic Scene Classifier 'SCAN'. This study will build on the evidence collected in&#xD;
      previous Nucleus 7 Sound Processor take home studies and will also aim to confirm the&#xD;
      in-booth performance of CP1110 and Nucleus 7 Sound Processors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2021</start_date>
  <completion_date type="Anticipated">November 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Prospective, pre-market, single-site, non-randomized.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Speech Reception Thresholds (SRT) assessed in spatially separated speech and noise (S0Nrearhalf).</measure>
    <time_frame>6 months</time_frame>
    <description>Paired difference in dB SRT (AuSTIN) between the CP1110 Sound Processor with ForwardFocus ON (SCAN) and ForwardFocus OFF (SCAN) (65 dB SPL S0Nrearhalf 4TB).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Speech Reception Thresholds (SRT) assessed in spatially separated speech and noise (S0N3).</measure>
    <time_frame>6 months</time_frame>
    <description>Paired difference in dB SRT (AuSTIN) between the CP1110 Sound Processor with ForwardFocus On (SCAN) and ForwardFocus OFF (SCAN) (65 dB SPL S0N3 Babble).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adult cochlear implant speech perception in quiet with the CP1110 Sound Processor and the Nucleus 7 Sound Processor.</measure>
    <time_frame>6 months</time_frame>
    <description>Paired difference in percentage CNC Words correct in quiet (50 dB) with the CP1110 Sound Processor and Nucleus 7 Sound Processor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adult cochlear implant subjective hearing performance and sound quality with the CP1110 Sound Processor and Nucleus 7 Sound Processor.</measure>
    <time_frame>6 months</time_frame>
    <description>Paired difference in Global Speech, Spatial and Qualities of Hearing Scale SSQ12 scores after experience with the CP1110 Sound Processor and Nucleus 7 Sound Responses on the SSQ12 have a minimum value of 0 and a maximum of 10, wherein a higher score means a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate acceptance and satisfaction of the CP1110 Sound Processor.</measure>
    <time_frame>6 months</time_frame>
    <description>Responses on the 'CP1110 Questionnaire 1' after at least 2 weeks of experience with the CP1110 Sound Processor and 'CP1110 Questionnaire 2' up to 6 months later.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Adult Cochlear Implant Recipients</condition>
  <arm_group>
    <arm_group_label>CP1110 Sound Processor System with ForwardFocus On (SCAN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CP1110 Sound Processor System with ForwardFocus Off (SCAN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nucleus 7 Sound Processor (model: CP1000) system</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CP1110 Sound Processor System</intervention_name>
    <description>Sound Processor</description>
    <arm_group_label>CP1110 Sound Processor System with ForwardFocus Off (SCAN)</arm_group_label>
    <arm_group_label>CP1110 Sound Processor System with ForwardFocus On (SCAN)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nucleus 7 Sound Processor (model: CP1000) system</intervention_name>
    <description>Sound Processor</description>
    <arm_group_label>Nucleus 7 Sound Processor (model: CP1000) system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18 years or older.&#xD;
&#xD;
          2. Post lingually deafened.&#xD;
&#xD;
          3. Implanted with the CI600 Series (CI612, CI632, CI622, CI624), CI500 Series (CI512,&#xD;
             CI532, CI522) or Freedom Series (CI24RE(CA), CI24RE(ST), CI422).&#xD;
&#xD;
          4. At least 6 months experience with a cochlear implant.&#xD;
&#xD;
          5. At least 3 months experience with a Nucleus 7 (CP1000) Sound Processor&#xD;
&#xD;
          6. Able to score 30% or more at +15 SNR with CI alone on a sentence in babble test&#xD;
&#xD;
          7. Willingness to participate in and to comply with all requirements of the protocol.&#xD;
&#xD;
          8. Fluent speaker in English as determined by the investigator&#xD;
&#xD;
          9. Willing and able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Additional disabilities that would prevent participation in evaluations.&#xD;
&#xD;
          2. Unrealistic expectations on the part of the subject, regarding the possible benefits,&#xD;
             risks and limitations that are inherent to the procedures.&#xD;
&#xD;
          3. Unable or unwilling to comply with the requirements of the clinical investigation as&#xD;
             determined by the Investigator.&#xD;
&#xD;
          4. Investigator site personnel directly affiliated with this study and/or their immediate&#xD;
             families; immediate family is defined as a spouse, parent, child, or sibling.&#xD;
&#xD;
          5. Cochlear employees or employees of Contract Research Organisations or contractors&#xD;
             engaged by Cochlear for the purposes of this investigation.&#xD;
&#xD;
          6. Currently participating, or participated in another interventional clinical&#xD;
             study/trial in the past 30 days or if less than 30 days, the prior investigation was&#xD;
             Cochlear sponsored and determined by the investigator to not impact clinical findings&#xD;
             of this investigation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kylie McClelland</last_name>
    <phone>+61296115909</phone>
    <phone_ext>6898</phone_ext>
    <email>kmcclelland@cochlear.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chris Warren</last_name>
    <phone>+61296115938</phone>
    <phone_ext>5938</phone_ext>
    <email>cwarren@cochlear.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cochlear Sydney</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2109</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esti Nel</last_name>
      <phone>+612 9428 6285</phone>
      <email>enel@cochlear.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 19, 2021</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

